This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm).

Acceptance Requirements

Have acquired resistance to an immune checkpoint inhibitor, defined as disease progression immediately following an initial response or stable disease

Pathologically confirmed stage IV NSCLC disease